Explore the latest news from Khondrion and its team.
NIJMEGEN, the Netherlands – Wednesday February 5th, 2020: Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies...
Study will examine impact on cognitive function from one of the most advanced disease-modifying drug treatments for mitochondrial disease in...
Khondrion becomes partner in DuSRA-VOILA collaboration
On Friday 10th January 2020, CEO Jan Smeitink participated in the Annual MitoAction Town Hall Meeting alongside other companies and organisations,...
Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces...
Members of the Khondrion team will be attending Mitochondrial Medicine 2019 on 11-13 December 2019. The event will bring together...
Khondrion Welcomes Hans Schikan, Former Prosensa CEO, to Advisory Board August 10, 2015, NIJMEGEN – Khondrion, the Dutch...
